Reply: Modifying the Poor Prognosis Associated with <sup>18</sup>F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of tumours associated with variable clinical presentations, growth rates, and prognoses. To improve the management of GEP-NENs, the WHO developed a classification system that enables tumours to be graded based on markers of cell proliferation in biopsy specimens. Indeed, histopathology has been a mainstay in the diagnosis of GEP-NENs, and the WHO grading system facilitates therapeutic decision-making; however, considerable intratumoural heterogeneity, predominantly comprising regional variations in proliferation rates, complicates the evaluation of tumour biology. The use of molecular imaging modalities to delineate the most-aggressive cell populations is becoming more widespread. In addition, molecular profiling is increasingly undertaken in the clinical setting, and genomic studies have revealed a number of chromosomal alterations in GEP-NENs, although the 'drivers' of neoplastic development have not been identified. Thus, our molecular understanding of GEP-NENs remains insufficient to inform on patient prognosis or selection for treatments, and the WHO classification continues to form the basis for management of this disease. Nevertheless, our increasing understanding of the molecular genetics and biology of GEP-NENs has begun to expose flaws in the WHO classification. We describe the current understanding of the molecular characteristics of GEP-NENs, and discuss how advances in molecular profiling measurements, including assays of circulating mRNAs, are likely to influence the management of these tumours.

show abstract

Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

Kidd

Modlin

Öberg

2016

Nat Rev Clin Oncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Reply: Modifying the Poor Prognosis Associated with ¹⁸F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

Cited by 1 publication

References 5 publications

Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

Contact Info

Product

Resources

About

Reply: Modifying the Poor Prognosis Associated with 18F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

Cited by 1 publication

References 5 publications

Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

Contact Info

Product

Resources

About

Reply: Modifying the Poor Prognosis Associated with ¹⁸F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)